Sage Journals: Discover world-class research

Abstract

Objective

To determine whether pre-treatment with high-dose ulinastatin provides enhanced postoperative oxygenation in patients who have undergone aortic valve surgery with moderate hypothermic cardiopulmonary bypass (CPB).

Methods

Patients who underwent aortic valve surgery with moderate hypothermic CPB were retrospectively evaluated. In total, 94 of 146 patients were included. The patients were classified into one of two groups: patients in whom ulinastatin (10,000 U/kg followed by 5,000 U/kg/h) was administered during CPB (Group U, n = 38) and patients in whom ulinastatin was not administered (Group C, n = 56). The PaO₂/FiO₂ ratio was calculated at the following time points: before CPB (pre-CPB), 2 h after weaning from CPB (post-CPB), and 6 h after arrival to the intensive care unit (ICU-6). The incidence of a low PaO₂/FiO₂ ratio was also compared among the time points.

Results

Group U showed a significantly higher PaO₂/FiO₂ ratio (F(4, 89.0) = 657.339) and a lower incidence of lung injury (PaO₂/FiO₂ ratio < 300) than Group C at the post-CPB and ICU-6 time points.

Conclusion

High-dose ulinastatin improved pulmonary oxygenation after CPB and in the early stages of the ICU stay in patients undergoing aortic valve surgery with CPB.

Keywords

Acute lung injury aortic valve surgery cardiopulmonary bypass intensive care unit pulmonary oxygenation ulinastatin

Introduction

Cardiopulmonary bypass (CPB) induces systemic inflammatory responses and postoperative organ injury, which increase perioperative mortality and morbidity.^1–4 Several studies have reported that ulinastatin has anti-inflammatory and organ-protective effects in animals and humans.^5–9 Ulinastatin attenuates the increase in systemic pro-inflammatory cytokines, enhances release of anti-inflammatory cytokines, and exerts beneficial effects on major organs including the heart, lungs, and kidneys.^9–11 Ulinastatin also reduces the duration of postoperative mechanical ventilation in patients who undergo cardiac surgery with CPB.^11,12 However, the effects of ulinastatin on CPB-induced lung injury and the postoperative oxygenation profile have not been evaluated.

Because ulinastatin has a short biphasic plasma half-life of 33 min and 2 h, its dosage and duration of infusion must be increased to cover the entire CPB period and thus attenuate CPB-induced organ injury.^13,14 We hypothesised that high-dose ulinastatin infusion during the CPB period would attenuate CPB-induced lung injury and improve postoperative pulmonary oxygenation. The present study was performed to test this hypothesis.

Patients and methods

Study population

This single-centre retrospective study was approved by the institutional review board of Konkuk University Medical Centre (KUH 1160051). We reviewed the medical records of patients who had undergone aortic valve repair or replacement under moderate hypothermic CPB from January 2012 to January 2015. Patient consent was not required because of the retrospective nature of the study.

The preoperative exclusion criteria were an age of <19 or >65 years, combined operation, emergency operation, re-do or tri-do operation, left ventricular ejection fraction of <50%, arrhythmia, ischaemic heart disease, pre-existing renal or hepatic dysfunction, and underlying lung disease. The intraoperative exclusion criterion was intraoperative application of an intra-aortic balloon pump. The postoperative exclusion criterion was reoperation to correct intractable postoperative bleeding.

The patients were classified into two groups. Group C comprised patients in whom ulinastatin was not administered. Group U comprised patients in whom 10,000 U/kg of ulinastatin was administered intravenously as a loading dose 30 min before CPB and 5,000 U/kg/h of ulinastatin was infused during the CPB period (Figure 1).

Figure 1.

Patient recruitment scheme. Twenty-six patients had more than two exclusion criteria. Group C: patients not administered ulinastatin, Group U: patients administered ulinastatin during cardiopulmonary bypass, op: operation, EF: left ventricular ejection fraction in preoperative transthoracic echocardiography, postop: postoperative.

Anaesthesia and surgery

Non-invasive monitoring was started upon the patient’s arrival in the operating room. Invasive arterial blood pressure monitoring was initiated before induction. Target-controlled infusions of propofol and remifentanil and a bolus and infusion of rocuronium were used. Mechanical ventilation was provided after tracheal intubation: an O₂/air mixture (FiO₂ of 0.5) of 4 L/min was applied with a tidal volume of 6 mL/kg and positive end-expiratory pressure (PEEP) of 7 to 8 mmHg, and the respiration rate was maintained at an end-tidal CO₂ tension of 35 to 40 mmHg. After inducing anaesthesia, central venous and pulmonary arterial catheters were placed and the central venous pressure (CVP), pulmonary arterial pressure (PAP), mixed venous oxygen saturation (SvO₂), and cardiac index (CI) were monitored continuously. A two- or three-dimensional trans-oesophageal echocardiographic examination was performed in accordance with the guidelines of the American Society of Echocardiography/Society of Cardiovascular Anaesthesiologists.

The surgical procedure was performed under CPB with moderate hypothermia (28°C–29°C). The pump was primed with 1500 to 1700 mL of acetate-buffered balanced crystalloid, 100 mL of 20% mannitol, and 100 mL of 20% albumin. Anticoagulation for CPB was initiated with 3 U/kg of heparin and monitored with an activated coagulation time of >400 s. After cross-clamping the aorta, cold crystalloid cardioplegia solution was administered. CPB was conducted with a non-pulsatile roller pump, polyvinyl chloride tubing, and a membrane oxygenator with hollow polypropylene fibres. The pump flow rate was adjusted to 2.0 to 2.5 L/min/m² to maintain a mean arterial blood pressure (MBP) of 60 to 70 mmHg. During CPB, continuous positive airway pressure of 5 mmHg was applied. Before weaning from CPB, modified ultrafiltration was applied with a flow rate of 200 mL/min/m² in all patients. Intermittent antegrade and retrograde cold crystalloid cardioplegia was administered every 30 min, and continuous topical cooling was applied during cardiac standstill. PaCO₂ was managed by α-stat during CPB.

CPB was weaned with or without inotropic support when the rectal temperature reached 36°C. Intraoperative fluid management was performed upon trans-oesophageal echocardiography monitoring. Dopamine was infused as a first-line inotropic agent to wean the patients from CPB as needed, and its infusion rate was adjusted to achieve a CI of >2.0 L/min/m² and MBP of >65 mmHg. The ventilation strategy applied during pre-CPB was restored. Blood in the CPB circuit and reservoir was given back to the patients before weaning from CPB. The threshold for transfusion of packed red blood cells (pRBCs) was a haematocrit of <21% during CPB and a haematocrit of <28% after CPB. Transfusion of fresh frozen plasma, cryoprecipitate, or platelets was performed upon the results of rotational thromboelastometry and routine laboratory coagulation-related tests. Intraoperative bleeding from the surgical site was salvaged and re-infused using a cell saver until closure of the chest wall.

Postoperative care

All patients were transferred to the intensive care unit (ICU) after surgery, where they underwent management according to institutional protocols. Volume–pressure-controlled ventilation was applied with a tidal volume of 6 mL/kg, respiratory rate of 10 to 18/min, PEEP of 5 to 8 mmHg, and FiO₂ of 60% Pressure support ventilation with a 10-cmH₂O pressure support level and 5-cmH₂O PEEP was performed upon recovery of spontaneous respiration.

The extubation criteria were a respiratory rate of 11 to 25 breaths/min, heart rate within 20% of baseline for at least for 1 h, PaO₂ of >70 mmHg, PaCO₂ of <48 mmHg, and pH of 7.35 to 7.50 on an arterial blood gas analysis.

Data acquisition

The primary objective was an intergroup comparison of the PaO₂/FiO₂ ratio 2 h after weaning from CPB (post-CPB). We also compared the PaO₂/FiO₂ ratio and its changes at the following time points: before CPB (pre-CPB), post-CPB, and 6 h after arrival in the ICU (ICU-6). The incidence rates of a low PaO₂/FiO₂ ratio (<200 and <300) were also compared. Haemodynamic variables including the heart rate, MBP, CVP, PAP, SvO₂, and CI were compared at these same time points.

The creatinine kinase-MB (CK-MB) concentration, high-sensitivity troponin-I (Tn-I) concentration, serum creatinine (s-Cr) concentration, glomerular filtration rate (GFR), and C-reactive protein (CRP) concentration were measured preoperatively, immediately after ICU arrival (ICU-0), and 12 h after ICU arrival (ICU-12).

Statistical analyses

We used an intention-to-treat strategy; that is, all patients were included in the analysis regardless of whether they had completed the study. Because some patients had missing data on the outcome variables, the missing data were completed using a last observation carried forward analysis. The distribution of continuous variables was first evaluated for normality using the Shapiro–Wilk test and a q-q plot. Normally distributed data are presented as mean ± standard deviation, and the groups were compared using parametric methods. The non-normally distributed data are expressed as median (interquartile range), and these data were analysed via non-parametric methods.

Because the patients’ age, height, CI, S_VO₂, and PaO₂/FiO₂ ratio passed the Shapiro–Wilk test, they were analysed parametrically. Weight, CPB duration, and number of transfused blood units did not pass the Shapiro–Wilk test; these data were therefore analysed non-parametrically. Because MBP, CVP, and PAP did not pass the Shapiro–Wilk test, we additionally checked the q-q plot, which did not show marked deviation from linearity. Therefore, the normal assumptions were applied for repeated-measures analysis of variance (RM-ANOVA). Because CI and S_vO₂ passed Mauchly’s sphericity test, they were analysed by RM-ANOVA with Greenhouse–Geisser correction followed by the paired t-test and Bonferroni correction (α = 0.05/3 and 0.0167). Because Mauchly’s sphericity test indicated that the assumption of sphericity had been violated for MBP [χ²(2) = 59.206, P < 0.001, Mauchly’s W = 0.518], CVP [χ²(2) = 77.383, P < 0.001, Mauchly’s W = 0.423], PAP [χ²(2) = 29.544, P < 0.001, Mauchly’s W = 0.720], and the PaO₂/FiO₂ ratio [χ²(5) = 16.012, P = 0.007, Mauchly’s W = 0.838], Wilks’ lambda multivariate ANOVA (MANOVA) followed by the paired t-test with Bonferroni correction (α = 0.05/3 and 0.0167 or α = 0.05/4 and 0.0125) was used.

Because s-Cr, GFR, CK-MB, Tn-I, and CRP did not pass the Shapiro–Wilk test and showed marked deviation from linearity, the data were analysed using Friedman’s test followed by the Mann–Whitney test with Bonferroni correction.

Descriptive variables were subjected to χ² analysis or Fisher’s exact test, as appropriate, and P-values of <0.05 were considered significant. Statistical analysis was performed using SPSS software (ver. 23.0; IBM Corp., Armonk, NY, USA).

Results

The medical records of 146 patients who underwent aortic valve surgery with moderate hypothermic CPB were screened, and 52 patients were excluded. Finally, 94 patients were classified into the 2 study groups (Group C, n = 56 and Group U, n = 38). The demographic data of the 94 patients are shown in Table 1. The preoperative variables were not different between the groups. The surgical procedure performed was either aortic valve leaflet repair (AVP) with/without aortic root remodelling or aortic valve replacement (AVR). There were no inter-group differences in the type of surgery: 45 of 56 patients in Group C and 32 of 38 patients in Group U underwent AVP, and the remaining patients underwent AVR.

Table 1.

Preoperative patient characteristics

	Group C (n = 56)	Group U (n = 38)	P-value
Age (years)	59 ± 15	59 ± 14	0.949
Sex (male/female)	21/35	10/28	0.258
Height (cm)	164 ± 10	165 ± 11	0.608
Weight (kg)	65 (54–73)	62 (56–69)	0.545
CK-MB (ng/mL)	1.10 (0.80–2.20)	1.10 (0.70–2.10)	0.726
Tn-I (ng/mL)	0.02 (0.02–0.08)	0.02 (0.02–1.10)	0.362
Increased Tn-I (>0.3 ng/mL)	10 (18.2)	10 (26.3)	0.348
s-Cr (mg/dL)	0.91 (0.76–1.04)	0.99 (0.80–1.12)	0.350
Smoking history
Current	10	3	0.169
Past	19	8	0.176

Data are presented as mean ± standard deviation, median (25%–75%), or number of patients (%), as appropriate. Group C: patients not administered ulinastatin, Group U: patients administered ulinastatin during cardiopulmonary bypass, CK-MB: serum creatinine kinase subtype MB (reference range: 0.0–6.6 ng/mL), Tn-I: high-sensitivity cardiac troponin I (reference range: 0.0–0.3 ng/mL), s-Cr: serum creatinine (reference range: 0.5–0.9 mg/dL).

The CPB duration, aortic cross-clamping time, and number of intraoperative transfused units were not different between the groups. The volumes of transfused pRBCs and fresh frozen plasma in the ICU were greater in Group U than Group C (Table 2).

Table 2.

Cardiopulmonary bypass duration and units of transfusion

	Group C (n = 56)	Group U (n = 38)	P-value
CPB duration (min)	178 (147–229)	180 (158–215)	0.815
Aorta cross-clamping time (min)	119 (103–142)	112 (93–135)	0.167
Haematocrit (%)
Preoperative	39 (32–42)	39 (32–41)	0.164
CPBmin	22 (20–25)	21 (19–23)	0.096
Transfusion
CPB
pRBC (U)	3 (0–4)	3 (0–4)	0.934
Post-CPB
pRBC (U)	1 (0–2)	1 (0–2)	0.648
FFP (U)	2 (0–3)	0.5 (0–2)	0.092
Platelet concentrate (U)	8 (0–8)	8 (0–8)	0.479
Cryoprecipitate (U)	0 (0–0)	0 (0–0)	0.131
ICU
pRBCs (U)	2 (0–4)	5 (3–6)	<0.001
FFP (U)	2 (0–3)	3 (2–4)	0.008
Platelet concentrate (U)	0 (0–0)	0 (0–8)	0.052
Cryoprecipitate (U)	0 (0–0)	0 (0–5)	0.107

Data are presented as median (25%–75%). Group C: patients not administered ulinastatin, Group U: patients administered ulinastatin during cardiopulmonary bypass, CPB duration: duration of application of cardiopulmonary bypass, CPBmin: minimum value during cardiopulmonary bypass, CPB: cardiopulmonary bypass, post-CPB: after weaning from cardiopulmonary bypass, ICU: intensive care unit, pRBCs: packed red blood cells, FFP: fresh frozen plasma.

Table 3 shows that there were no differences in the haemodynamic data between the two groups (MBP: [F(3, 89.0) = 0.521: Wilks’ lambda = 0.983, partial eta² = 0.017], CVP: [F(3, 89.0) = 0.022: Wilks’ lambda = 0.999, partial eta² = 0.001], and PAP: [F(3, 89.0) = 0.403: Wilks’ lambda = 0.987, partial eta² = 0.013]).

Table 3.

Haemodynamic parameters

	Group C (n = 56)	Group U (n = 38)	P-value
MBP (mmHg)
pre-CPB	75 ± 9	75 ± 11	0.669
post-CPB	66 ± 15	68 ± 16
ICU-6	65 ± 12	67 ±14
CVP (mmHg)
pre-CPB	8 ± 3	8 ± 3	0.996
post-CPB	10 ± 5	10 ± 2
ICU-6	10 ± 5	10 ± 2
PAP (mmHg)
pre-CPB	19 ± 5	19 ± 7	0.751
post-CPB	18 ± 4	17 ± 3
ICU-6	20 ± 5	20 ± 6
CI (L/min/m²)
pre-CPB	2.5 ± 0.7	2.6 ± 0.9	0.943
post-CPB	2.5 ± 0.7	2.6 ± 0.6
SvO₂ (%)
pre-CPB	78 ± 6	78 ± 7	0.926
post-CPB	78 ± 8	78 ± 6

Data are presented as mean ± standard deviation. Group C: patients not administered ulinastatin, Group U: patients administered ulinastatin during cardiopulmonary bypass, pre-CPB: before cardiopulmonary bypass, post-CPB: 2 h after weaning from cardiopulmonary bypass, ICU-6: within 6 h after admission to the intensive care unit, MBP: mean arterial blood pressure, CVP: central venous pressure, PAP: mean pulmonary artery pressure, CI: cardiac index, SvO₂: mixed venous oxygen saturation. P-values represent overall inter-group differences in repeated-measures analysis of variance or multivariate analysis of variance, as appropriate.

The PaO₂/FiO₂ ratio did not differ between the groups at the pre-CPB time point. However, the PaO₂/FiO₂ ratio was higher in Group U than Group C at post-CPB and ICU-6 (P < 0.05). The MANOVA results showed a difference in the change in the PaO₂/FiO₂ ratio between two groups [F(4, 89.0) = 657.339, P < 0.001: Wilks’ lambda = 0.033, partial eta² = 0.967]. The incidence of a PaO₂/FiO₂ ratio of <300 was lower in Group U than Group C at the same time point (Table 4).

Table 4.

Changes in PaO₂/FiO₂ ratio and incidence of low PaO₂/FiO₂ ratio

	Group C (n = 56)	Group U (n = 38)	P-value
PaO₂/FiO₂ ratio
pre-CPB	423 ± 87	432 ± 105	<0.001
post-CPB	305 ± 76	406 ± 103*
ICU-6	328 ± 84	393 ± 110*
Incidence of PaO₂/FiO₂ ratio of <200
pre-CPB	1(1.8)	2 (5.3)	0.563
post-CPB	3 (5.4)	1 (2.6)	0.645
ICU-6	2 (3.6)	2 (5.3)	1.000
Incidence of PaO₂/FiO₂ ratio of <300
pre-CPB	3 (5.4)	4 (10.5)	0.435
post-CPB	28 (50.0)	6 (15.8)	0.001
ICU-6	24 (42.9)	6 (15.8)	0.006

Data are presented as mean ± standard deviation or number of patients (%). Group C: patients not administered ulinastatin, Group U: patients administered ulinastatin during cardiopulmonary bypass, pre-CPB: before cardiopulmonary bypass, post-CPB: 2 h after weaning from cardiopulmonary bypass, ICU-6: within 6 h after admission to the intensive care unit. P-values of PaO₂/FiO₂ ratio represent overall inter-group differences in repeated-measures analysis of variance or multivariate analysis of variance, as appropriate. *P < 0.05 compared with Group C. P-values of incidence of low PaO₂/FiO₂ ratio represent overall inter-group differences in χ² analysis or Fisher’s exact test, as appropriate.

The length of ventilatory support was not different between Group C and Group U (16 (13–18) vs. 15.5 (11.5–19.5) h, respectively).

CK-MB, Tn-I, s-Cr, GFR, and CRP did not differ between the groups (Table 5).

Table 5.

Changes in cardiac enzymes, indices of renal performance, and CRP

	Group C (n = 56)	Group U (n = 38)	P-value
CK-MB (ng/mL)
pre-CPB	1.1 (0.8–2.2)	1.1 (0.7–2.1)	0.798
ICU-0	16.6 (11.6–31.9)	16.0 (11.0–28.1)
ICU-12	13.6 (8.7–24.4)	14.5 (7.5–20.9)
Tn-I (pg/mL)
pre-CPB	0.02 (0.02–0.08)	0.02 (0.02–1.10)	0.988
ICU-0	4.18 (1.94–6.72)	4.24 (1.13–7.14)
ICU-12	4.14 (2.85–7.40)	4.62 (1.48–8.85)
s-Cr (mg/dL)
pre-CPB	0.9 (0.8–1.0)	1.0 (0.8–1.1)	0.628
ICU-0	0.8 (0.7–1.0)	0.8 (0.7–1.0)
ICU-12	0.9 (0.7–1.0)	0.9 (0.6–1.0)
GFR (mL/min/1.73 m²)
pre-CPB	80 (68–90)	79 (64–90)	0.785
ICU-0	90 (78–90)	90 (73–90)
ICU-12	89 (78–90)	81 (72–90)
CRP (mg/dL)
pre-CPB	0.11 (005–0.23)	0.05 (003–0.13)	0.095
ICU-0	0.10 (0.06–0.14)	0.07 (0.04–0.18)
ICU-12	5.88 (4.12–7.24)	4.22 (2.40–7.13)

Data are presented as median (25%–75%). Group C: patients not administered ulinastatin-treatment, Group U: patients administered ulinastatin during cardiopulmonary bypass, CK-MB: serum creatinine kinase subtype MB (reference range: 0.0–6.6 ng/mL), Tn-I: high-sensitivity cardiac troponin-I (reference range: 0.0–0.3 ng/mL), s-Cr: serum creatinine (reference range: 0.5–0.9 mg/dL), GFR: glomerular filtration rate (reference value: >90 mL/min/1.73 m²), CRP: high-sensitivity C-reactive protein (reference range: 0.01–0.3 mg/dL), pre-CPB: before applying cardiopulmonary bypass, ICU-0: immediately after admission to the intensive care unit, ICU-12: 12 h after admission to the intensive care unit. P-values represent overall inter-group differences in repeated-measures analysis of variance or multivariate analysis of variance, as appropriate.

Discussion

In the present study, high-dose ulinastatin infusion during CPB provided a higher PaO₂/FiO₂ ratio after weaning from CPB and in the early stage in the ICU. The higher PaO₂/FiO₂ ratio in ulinastatin-treated patients may suggest a reduction in postoperative morbidity and mortality, as shown in other studies.^15–17 In previous studies, ulinastatin attenuated ischaemia–reperfusion-induced lung injury by inhibition of myeloperoxidase activity in lung tissue and a decrease in the systemic expression of tumour necrosis factor-α in a rat model and attenuated the release of interleukin-6 and -8 immediately after CPB. The degree of changes in the respiratory index and intrapulmonary shunt was correlated with the interleukin-8 level.^6,9 However, these inflammatory cytokines were not analysed in the present study because they are not included as routine laboratory tests for patients undergoing cardiac surgery in our institution.

The results of the present study did not show improved clinical outcomes, such as shortening of the mechanical ventilation time, intubation time, or ICU stay. Several studies have revealed shortened durations of mechanical ventilation, intubation, and ICU stay in patients treated with ulinastatin. Zhang et al.¹¹ concluded that ulinastatin treatment might shorten the duration of mechanical ventilation as well as the duration of intubation, but the ICU stay was not shortened. He et al.¹² also found that the use of ulinastatin reduced the duration of mechanical ventilation, but the length of ICU stay was not different. Song et al.¹⁸ found that patients treated with ulinastatin had shorter ICU stays than the control group. Xu et al.¹⁰ also concluded that high-dose ulinastatin shortened the ICU stay after application of CPB with deep hypothermic circulatory arrest.

We used high-dose ulinastatin during the entire CPB period (total dose of 20,000 U/kg with a 2-h CPB period and 25,000 U/kg with a 3-h CPB period). Previous studies also recommended a higher dose of ulinastatin (5,000–20,000 U/kg) to overcome the dose-dependent heterogeneity in terms of exerting organ-protective effects.^10,11

Despite the improved oxygenation profile, which is probably due to ulinastatin’s attenuation of CPB-induced acute lung injury, we found no positive improvement in ultimate outcomes such as shortening of the duration of intubation and ventilator support. These findings are not in accordance with those of Esteve et al.,¹⁹ who reported that the PaO₂/FiO₂ ratio 3 h after ICU admission may be useful to predict the outcome of cardiac surgical patients during their hospital stay. We may consider two major factors. First, because the duration of action of ulinastatin is much shorter than the length of ventilatory support, ulinastatin cannot attenuate the inflammatory stress that occurs after CPB. Second, transfusion-related acute lung injury could aggravate postoperative pulmonary function. The volume of transfused pRBCs in the ICU was greater in Group U than in Group C in this study (5 vs. 2 U, respectively). This discrepancy suggests ulinastatin's additional efficacy for attenuating transfusion-related acute lung injury in cardiac surgery.¹⁸

In this study, we identified no clinical outcomes suggesting the beneficial effects of ulinastatin in attenuating CPB-induced myocardial or kidney injury. The absence of inter-group differences in myocardiac biomarkers, such as Tn-I and CK-MB, contradict the findings of a previous report showing significant reductions in the levels of cardiac markers and blood pressure in patients undergoing ulinastatin treatment, suggesting ulinastatin’s protective effects against myocardial injury.¹¹ The routine use of ultrafiltration at the end of CPB to remove free water and improve post-CPB pulmonary function might affect the level of myocardial biomarkers.^20,21 The s-Cr concentration and GFR showed no inter-group differences in our study. A few studies have shown that ulinastatin may reduce the risk of acute kidney injury after CPB, but this finding is controversial because of the absence of a difference in the s-Cr or cystatin C concentration after aortic valve surgery with CPB.^22,23

This study has some limitations. First, because this study involved a retrospective analysis of patients’ medical records, no analyses of inflammatory cytokines were included; however, such analyses might have supported ulinastatin’s efficacy in attenuating anti-inflammatory cascades and organ protection.²⁴ Instead, CRP was analysed, indicating the degree of the anti-inflammatory effects of neutrophil elastase inhibitors,^25,26 and showed no significant inter-group differences in our study. Second, we analysed the PaO₂/FiO₂ ratio, which is inferior to the alveolar-arterial O₂ tension difference, P(A-a)O₂, or ratio of P(A-a)O₂ to PaO₂ in the early diagnosis of acute lung injury.⁸ Third, our study’s primary outcome was confined to the immediate post-CPB period; other clinical outcomes beyond the immediate postoperative period were not analysed. Finally, because the study was performed in a retrospective manner, it was not possible to standardise or minimise possible biases that could have affected the outcome, and the data of only 94 patients were included in the final analyses. However, the type of surgery was confined to aortic valvular surgery, so the patients had uniform clinical courses.

In conclusion, ulinastatin treatment during the CPB period provided a better oxygenation profile after CPB and in the early stages in the ICU in patients undergoing aortic valve surgery with moderate hypothermic CPB.

Footnotes

Acknowledgement

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see:

Authors’ contributions

Research conception and design: KYR, TYK. Data analysis and interpretation: KYR, TYS, JDK, NM. Statistical analysis: HK. Drafting of the manuscript: KYR, HK. Critical revision of the manuscript: TYK. Approval of final manuscript: all authors.

Disclosure

The preliminary study described in this manuscript was presented as an abstract at the 42nd Annual Meeting of the Japanese Society of Intensive Care Medicine.

Declaration of conflicting interests

The authors declare that there are no conflicts of interest.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This paper was supported by Konkuk University. This study was supported by Konkuk University Medical Centre.

References

Laffey

Boylan

and Cheng

DC.

The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist.

Anesthesiology 2002; 97: 215–252.

Picone

Lutz

Finck

et al . Multiple sequential insults cause post-pump syndrome. Ann Thorac Surg 1999; 67: 978–985.

Ito

Hamano

Gohra

et al . Relationship between respiratory distress and cytokine response after cardiopulmonary bypass. Surg Today 1997; 27: 220–225.

Kawamura

Wakusawa

Okada

et al . Elevation of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin 8 and 6 in reperfusion injury. Can J Anaesth 1993; 40: 1016–1021.

Cao

Okazaki

Naito

et al . Ulinastatin attenuates reperfusion injury in the isolated blood-perfused rabbit heart. Ann Thorac Surg 2000; 69: 1121–1126.

Ren

Zhu

et al . Ulinastatin attenuates lung ischemia-reperfusion injury in rats by inhibiting tumor necrosis factor alpha. Transplant Proc 2006; 38: 2777–2779.

Nakahama

Obata

and Sugita

Ulinastatin ameliorates acute ischemic renal injury in rats. Ren

Fail 1996; 18: 893–898.

Yuan

SM.

Postperfusion lung syndrome: Respiratory mechanics, respiratory indices and biomarkers.

Ann Thorac Med 2015; 10: 151–157.

Nakanishi

Takeda

Sakamoto

et al . Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 2006; 34: 1351–1357.

10.

Zou

Zhang

et al . Effects of high-dose ulinastatin on inflammatory response and pulmonary function in patients with type-A aortic dissection after cardiopulmonary bypass under deep hypothermic circulatory arrest. J Cardiothorac Vasc Anesth 2013; 27: 479–484.

11.

Zhang

Zeng

Cao

et al . Effect of urinary protease inhibitor (ulinastatin) on cardiopulmonary bypass: a meta-analysis for china and Japan. Plos one 2014; 9: e113973.

12.

Lin

et al . Effect of the urinary tryptin inhibitor ulinastatin on cardiopulmonary bypass–related inflammatory response and clinical outcomes: A meta-analysis of randomized controlled trials. Clin Ther 2015; 37: 643–653.

13.

Jonsson-Berling

and Ohlsson

Distribution and elimination of intravenously injected urinary trypsin inhibitor.

Scand J Clin Lab Invest 1991; 51: 549–557.

14.

Bingyang

Jinping

Mingzheng

et al.

Effects of urinary protease inhibitor on inflammatory response during on-pump coronary revascularisation. Effect of ulinastatin on inflammatory response. J Cardiovasc Surg (Torino) 2007; 48: 497–503.

15.

Rady

Ryan

and Starr

NJ.

Early onset of acute pulmonary dysfunction after cardiovascular surgery: risk factors and clinical outcome.

Crit Care Med 1997; 25: 1831–1839.

16.

Asimakopoulos

Smith

Ratnatunga

et al . Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg 1999; 68: 1107–1115.

17.

Wan

Yim

et al . Pulmonary dysfunction after cardiac surgery. Chest. 2002; 121: 1269–1277.

18.

Song

Kang

Kim

et al . The effect of ulinastatin on postoperative blood loss in patients undergoing open heart surgery with cardiopulmonary bypass. J Int Med Res 2011; 39: 1201–1210.

19.

Esteve

Lopez-Delgado

Javierre

et al . Evaluation of the PaO2/FiO2 ratio after cardiac surgery as a predictor of outcome during hospital stay. BMC Anesthesiol 2014; 14: 83.

20.

Tassani

Richter

Eising

et al . Influence of combined zero-balanced and modified ultrafiltration on the systemic inflammatory response during coronary artery bypass grafting. J Cardiothorac Vasc Anesth 1999; 13: 285–291.

21.

Grünenfelder

Zünd

Schoeberlein

et al . Modified ultrafiltration lowers adhesion molecule and cytokine levels after cardiopulmonary bypass without clinical relevance in adults. Eur J Cardiothorac Surg 2000; 17: 77–83.

22.

Wan

Xie

Gendoo

et al . Ulinastatin administration is associated with a lower incidence of acute kidney injury after cardiac surgery: a propensity score matched study. Crit Care 2016; 20: 42.

23.

Kim

Choi

et al . Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass. Korean J Anesthesiol 2012; 62: 148–153.

24.

Chen

Wang

Luo

et al . Ulinastatin reduces urinary sepsis-related inflammation by upregulating IL-10 and downregulating TNF-α levels. Mol Med Rep 2013; 8: 29–34.

25.

Inoue

Oka

Kitamura

et al . Neutrophil elastase inhibitor sivelestat attenuates perioperative inflammatory response in pediatric heart surgery with cardiopulmonary bypass. Int Heart J 2013; 54: 149–153.

26.

Kohira

Oka

Inoue

et al . Effect of the neutrophil elastase inhibitor sivelestat on perioperative inflammatory response after pediatric heart surgery with cardiopulmonary bypass: a prospective randomized study. Artif Organs 2013; 37: 1027–1033.

High-dose ulinastatin improves postoperative oxygenation in patients undergoing aortic valve surgery with cardiopulmonary bypass: A retrospective study

Abstract

Objective

Methods

Results

Conclusion

Keywords

Introduction

Patients and methods

Study population

Anaesthesia and surgery

Postoperative care

Data acquisition

Statistical analyses

Results

Discussion

Footnotes

Acknowledgement

Authors’ contributions

Disclosure

Declaration of conflicting interests

Funding

References